TW202342451A - Kif18a抑制劑之合成 - Google Patents

Kif18a抑制劑之合成 Download PDF

Info

Publication number
TW202342451A
TW202342451A TW112103047A TW112103047A TW202342451A TW 202342451 A TW202342451 A TW 202342451A TW 112103047 A TW112103047 A TW 112103047A TW 112103047 A TW112103047 A TW 112103047A TW 202342451 A TW202342451 A TW 202342451A
Authority
TW
Taiwan
Prior art keywords
compound
solvent
alkyl
acid
benzyl
Prior art date
Application number
TW112103047A
Other languages
English (en)
Chinese (zh)
Inventor
西貝斯汀 凱爾
丹尼爾 傑洛德 格林
麥可 湯馬士 科貝特
卡洛琳 魏
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202342451A publication Critical patent/TW202342451A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW112103047A 2022-01-26 2023-01-30 Kif18a抑制劑之合成 TW202342451A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26
US63/303,470 2022-01-26

Publications (1)

Publication Number Publication Date
TW202342451A true TW202342451A (zh) 2023-11-01

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112103047A TW202342451A (zh) 2022-01-26 2023-01-30 Kif18a抑制劑之合成

Country Status (12)

Country Link
US (1) US20250129050A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469437A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025505892A (cg-RX-API-DMAC10.html)
KR (1) KR20240144140A (cg-RX-API-DMAC10.html)
CN (1) CN118922406A (cg-RX-API-DMAC10.html)
AR (1) AR128353A1 (cg-RX-API-DMAC10.html)
AU (1) AU2023211589A1 (cg-RX-API-DMAC10.html)
CA (1) CA3248925A1 (cg-RX-API-DMAC10.html)
IL (1) IL314221A (cg-RX-API-DMAC10.html)
MX (1) MX2024009163A (cg-RX-API-DMAC10.html)
TW (1) TW202342451A (cg-RX-API-DMAC10.html)
WO (1) WO2023146973A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
CR20250087A (es) 2022-08-18 2025-07-11 Accent Therapeutics Inc Inhibidores de kif18a y usos de estos
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
CN121693499A (zh) * 2023-08-16 2026-03-17 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL283639B2 (en) * 2018-12-20 2024-06-01 Amgen Inc Kif18a inhibitors
JP2023521802A (ja) * 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのkif18a阻害剤

Also Published As

Publication number Publication date
CA3248925A1 (en) 2023-08-03
AR128353A1 (es) 2024-04-24
WO2023146973A1 (en) 2023-08-03
AU2023211589A1 (en) 2024-07-25
US20250129050A1 (en) 2025-04-24
KR20240144140A (ko) 2024-10-02
IL314221A (en) 2024-09-01
EP4469437A1 (en) 2024-12-04
JP2025505892A (ja) 2025-03-03
MX2024009163A (es) 2024-08-09
CN118922406A (zh) 2024-11-08

Similar Documents

Publication Publication Date Title
TWI475992B (zh) 製備4-{4-[({[4-氯-3-(三氯甲基)-苯基]胺基}羰基)胺基]-3-氟苯氧基}-n-甲基吡啶-2-甲醯胺、其鹽及單水合物之方法
US10807953B2 (en) Processes and intermediates for the preparation of Pimavanserin
US20250129050A1 (en) Synthesis of a kif18a inhibitor
JP7157752B2 (ja) Ag-10、その中間体及びその塩の調製方法
KR20160072127A (ko) Pde4 억제제의 제조 방법
AU2020267299A1 (en) Methods of making protein deacetylase inhibitors
JP2025505892A5 (cg-RX-API-DMAC10.html)
BRPI0715831A2 (pt) processo para produÇço da 1-(3,4-diclorobenzil)-5-octilbiguanida ou um sal da mesma
KR20140013232A (ko) N-(2-히드록시에틸)니코틴아미드 및 니코란딜의 제조방법
EP4063351A1 (en) Preparation method of quinoline derivative compounds
RU2466983C2 (ru) Способ синтеза сульфонилгалогенидов и сульфонамидов из солей сульфоновых кислот
WO2015196926A1 (en) Process for the preparation of polymorphs of imidacloprid
EA052216B1 (ru) Синтез ингибитора kif18a
WO2011036648A1 (en) Polymorphs of sorafenib acid addition salts
CN111100111B (zh) 一种制备苯并噻吩衍生物的方法
CN103339124A (zh) 二(芳氨基)芳基化合物的制备方法及其合成中间体
EP2829540A1 (en) Synthesis of substituted aminopyridines